ITHACA, N.Y.--(BUSINESS WIRE)--Rheonix today announced that it has completed development of a novel microarray production technology to create a high-fidelity microarray, the Hy-Fi Microarray™. Hy-Fi Microarrays provide simple, multiplexed end point detection for molecular assays and, in particular, a novel method to detect single nucleotide polymorphisms (SNPs) on the Rheonix CARD® system. While Rheonix intends to apply this proprietary microarray technology to improve SNP detection, the technology is broadly applicable to meet the need for high volume production of high quality/low density microarrays and therefore, has licensing potential for use in multiple research and clinical applications. Together, these new technology components will allow Rheonix to produce higher quality and more accurate diagnostic results.
